• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本儿童、青少年和青年 2016-2018 年癌症发病率和治疗医院类型。

Cancer incidence and type of treatment hospital among children, adolescents, and young adults in Japan, 2016-2018.

机构信息

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

National Cancer Center Institute for Cancer Control, Tokyo, Japan.

出版信息

Cancer Sci. 2023 Sep;114(9):3770-3782. doi: 10.1111/cas.15892. Epub 2023 Jul 6.

DOI:10.1111/cas.15892
PMID:37414740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10475761/
Abstract

Cancer in children, adolescents, and young adults (AYAs) although rare, is the leading disease-specific cause of death in Japan. This study aims to investigate cancer incidence and type of treatment hospital among children and AYAs in Japan. Cancer incidence data (2016-2018) for those aged 0-39 years were obtained from the Japanese population-based National Cancer Registry. Cancer types were classified according to the 2017 update of the International Classification of Childhood Cancer (Third Edition), and AYA Site Recode 2020 Revision. Cases were also categorized into three groups: those treated at core hospitals for pediatric cancer treatment (pediatric cancer hospitals [PCHs]), those treated at designated cancer care hospitals, and those treated at nondesignated hospitals. The age-standardized incidence rate was 166.6 (per million-person years) for children (age 0-14 years) and 579.0 for AYAs (age 15-39 years) (including all cancers and benign or uncertain-behavior central nervous system [CNS] tumors). The type of cancer varied with age: hematological malignancies, blastomas, and CNS tumors were common in children under 10 years, malignant bone tumors and soft tissue sarcomas were relatively common in teenagers, and in young adults over 20 years, carcinomas in thyroid, testis, gastrointestinal, female cervix, and breast were common. The proportion of cases treated at PCHs ranged from 20% to 30% for children, 10% or less for AYAs, and differed according to age group and cancer type. Based on this information, the optimal system of cancer care should be discussed.

摘要

儿童、青少年和青年期癌症(AYA)尽管罕见,但在日本是导致特定疾病死亡的主要原因。本研究旨在调查日本儿童和 AYA 的癌症发病率和治疗医院类型。0-39 岁人群的癌症发病率数据(2016-2018 年)来自基于人群的日本国家癌症登记处。根据 2017 年版《儿童癌症国际分类(第三版)》和 AYA 部位重编码 2020 年修订版对癌症类型进行分类。病例还分为三组:在儿科癌症治疗核心医院(儿科癌症医院 [PCH])治疗的病例、在指定癌症护理医院治疗的病例和在非指定医院治疗的病例。儿童(0-14 岁)的年龄标准化发病率为 166.6(每百万人口年),AYA(15-39 岁)为 579.0(包括所有癌症和良性或不确定行为中枢神经系统 [CNS]肿瘤)。癌症类型随年龄而异:10 岁以下儿童常见血液系统恶性肿瘤、胚细胞瘤和 CNS 肿瘤,青少年中常见恶性骨肿瘤和软组织肉瘤,20 岁以上青年中常见甲状腺、睾丸、胃肠道、女性宫颈和乳腺的癌。在 PCH 治疗的病例比例在儿童中为 20%至 30%,在 AYA 中为 10%或更低,且根据年龄组和癌症类型而有所不同。基于这些信息,应讨论癌症治疗的最佳系统。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/aa5fc8c42d4e/CAS-114-3770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/9c2d3c29e815/CAS-114-3770-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/95af26fc11e7/CAS-114-3770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/aa5fc8c42d4e/CAS-114-3770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/9c2d3c29e815/CAS-114-3770-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/95af26fc11e7/CAS-114-3770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a7c/10475761/aa5fc8c42d4e/CAS-114-3770-g001.jpg

相似文献

1
Cancer incidence and type of treatment hospital among children, adolescents, and young adults in Japan, 2016-2018.日本儿童、青少年和青年 2016-2018 年癌症发病率和治疗医院类型。
Cancer Sci. 2023 Sep;114(9):3770-3782. doi: 10.1111/cas.15892. Epub 2023 Jul 6.
2
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告:儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
3
[Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002-2010].[2002 - 2010年上海儿童恶性实体瘤的近期发病情况及趋势]
Zhonghua Er Ke Za Zhi. 2013 Apr;51(4):288-94.
4
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
5
Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011.2009 - 2011年日本儿童、青少年及青年癌症发病率
Jpn J Clin Oncol. 2017 Aug 1;47(8):762-771. doi: 10.1093/jjco/hyx070.
6
Characteristics of Cancers in Adolescents and Young Adults Compared with Those in Adults in Their 60s: A Single-Center Experience.青少年和 60 多岁成年人癌症特征比较:单中心经验。
Oncology. 2022;100(3):140-147. doi: 10.1159/000520291. Epub 2022 Jan 31.
7
Cancer incidence and survival among adolescents and young adults in Korea.韩国青少年和青年的癌症发病率与生存率
PLoS One. 2014 May 1;9(5):e96088. doi: 10.1371/journal.pone.0096088. eCollection 2014.
8
Cancer in adolescents and young adults in Japan: epidemiology and cancer strategy.日本青少年和年轻成年人中的癌症:流行病学和癌症策略。
Int J Clin Oncol. 2022 Jan;27(1):7-15. doi: 10.1007/s10147-021-02064-x. Epub 2021 Nov 15.
9
Impact of treatment site in adolescents and young adults with central nervous system tumors.青少年和年轻成年人中枢神经系统肿瘤治疗部位的影响。
J Natl Cancer Inst. 2014 Sep 1;106(8):dju166. doi: 10.1093/jnci/dju166. Print 2014 Aug.
10
Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.日本青少年和青年成人骨肉瘤患者的描述性流行病学及预后情况
BMC Musculoskelet Disord. 2018 Aug 18;19(1):297. doi: 10.1186/s12891-018-2217-1.

引用本文的文献

1
Rhabdomyosarcoma Requiring Ovarian Transposition Release for Recurrent Severe Ovulation Pain Following Laparoscopic Ovarian Transposition: A Case Report.腹腔镜卵巢移位术后复发性严重排卵痛需行卵巢移位松解术的横纹肌肉瘤:一例报告
Reprod Med Biol. 2025 Jun 24;24(1):e12665. doi: 10.1002/rmb2.12665. eCollection 2025 Jan-Dec.
2
Rehabilitation nursing for brain tumor patients: a scoping review.脑肿瘤患者的康复护理:一项范围综述
BMC Med Educ. 2025 Jun 2;25(1):821. doi: 10.1186/s12909-025-07423-0.
3
Global patterns and burden of soft tissue and extraosseous sarcomas: trends from 1990 to 2021.

本文引用的文献

1
[Geographic information in National Cancer Registry data: Overseas examples and challenges in Japan].[国家癌症登记数据中的地理信息:海外实例及日本面临的挑战]
Nihon Koshu Eisei Zasshi. 2023 Mar 23;70(3):163-170. doi: 10.11236/jph.22-093. Epub 2023 Feb 10.
2
International benchmarking of childhood cancer survival by stage at diagnosis: The BENCHISTA project protocol.国际儿童癌症诊断时分期的生存基准比较:BENCHISTA 项目方案。
PLoS One. 2022 Nov 3;17(11):e0276997. doi: 10.1371/journal.pone.0276997. eCollection 2022.
3
A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors.
软组织和骨外肉瘤的全球模式与负担:1990年至2021年的趋势
BMC Cancer. 2025 Apr 17;25(1):725. doi: 10.1186/s12885-025-14136-6.
4
Geographical Discrepancy in Medical Care Access Among Children, Adolescents, and Young Adults With Cancer in Japan, 2016-2019.2016 - 2019年日本癌症儿童、青少年和青年获得医疗服务的地理差异
Cancer Sci. 2025 Jul;116(7):1972-1983. doi: 10.1111/cas.70069. Epub 2025 Apr 2.
5
Comparison of lifetime attributable risk of post-irradiation secondary cancer of boron neutron capture therapy, proton beam therapy, and X-ray therapy for pediatric and adolescent and young adult patients.硼中子俘获疗法、质子束疗法和X射线疗法对儿童、青少年和年轻成年患者照射后继发性癌症终生归因风险的比较。
Clin Transl Radiat Oncol. 2025 Jan 12;51:100921. doi: 10.1016/j.ctro.2025.100921. eCollection 2025 Mar.
6
Epidemiology and clinical features of childhood malignant solid tumors in a single center in southwest China over 24 years.中国西南某单一中心24年儿童恶性实体瘤的流行病学及临床特征
BMC Pediatr. 2025 Jan 7;25(1):12. doi: 10.1186/s12887-024-05360-3.
7
Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors.儿童和青年复发性或难治性实体瘤患者他米巴罗汀的群体药代动力学。
Curr Oncol. 2024 Nov 14;31(11):7155-7164. doi: 10.3390/curroncol31110527.
8
Clinical significance of sarcopenia in children with neuroblastic tumors.神经母细胞瘤患儿肌肉减少症的临床意义。
Pediatr Surg Int. 2024 Aug 21;40(1):237. doi: 10.1007/s00383-024-05815-9.
9
Preoperative dexamethasone administration in reducing the incidence of nausea and vomiting after thyroidectomy: a systematic review and meta-analysis of drug dosage.术前给予地塞米松降低甲状腺切除术后恶心呕吐发生率:药物剂量的系统评价和荟萃分析
Gland Surg. 2024 Feb 29;13(2):189-198. doi: 10.21037/gs-23-260. Epub 2024 Feb 23.
BAK1 常见缺失会降低增强子活性,并增加颅内生殖细胞瘤的风险。
Nat Commun. 2022 Aug 2;13(1):4478. doi: 10.1038/s41467-022-32005-9.
4
Cutaneous malignant melanoma incidence is strongly associated with European depigmented skin type regardless of ambient ultraviolet radiation levels: evidence from Worldwide population-based data.无论环境紫外线辐射水平如何,皮肤恶性黑色素瘤的发病率都与欧洲浅色皮肤类型密切相关:基于全球人群数据的证据。
AIMS Public Health. 2022 Mar 17;9(2):378-402. doi: 10.3934/publichealth.2022026. eCollection 2022.
5
Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year's experience of national centralization.荷兰儿童肾肿瘤的特征和结局:国家集中化的头五年经验。
PLoS One. 2022 Jan 13;17(1):e0261729. doi: 10.1371/journal.pone.0261729. eCollection 2022.
6
Cancer in adolescents and young adults in Japan: epidemiology and cancer strategy.日本青少年和年轻成年人中的癌症:流行病学和癌症策略。
Int J Clin Oncol. 2022 Jan;27(1):7-15. doi: 10.1007/s10147-021-02064-x. Epub 2021 Nov 15.
7
Comparative analysis of the clinical characteristics and outcomes of patients with Wilms tumor in the United Kingdom and Japan.英国和日本肾母细胞瘤患者临床特征及预后的比较分析。
Pediatr Blood Cancer. 2021 Oct;68(10):e29143. doi: 10.1002/pbc.29143. Epub 2021 May 31.
8
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?韩国甲状腺癌发病率呈下降趋势:韩国发生了什么?
Cancer Med. 2021 Jun;10(12):4087-4096. doi: 10.1002/cam4.3926. Epub 2021 May 12.
9
Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15-39 Years): A Population-Based Study in The Netherlands 1990-2016.青少年和青年(15 - 39岁)癌症诊断的发病率、生存率和死亡率趋势:1990 - 2016年荷兰基于人群的研究
Cancers (Basel). 2020 Nov 18;12(11):3421. doi: 10.3390/cancers12113421.
10
Incidence of childhood renal tumours: An international population-based study.儿童肾肿瘤发病率:一项国际基于人群的研究。
Int J Cancer. 2020 Dec 15;147(12):3313-3327. doi: 10.1002/ijc.33147. Epub 2020 Jul 22.